Physician profile
Lawrence E Perry
NPI 1407071558
$8,573.35
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,839 · 2020: $1,686 · 2021: $2,159 · 2022: $1,434 · 2023: $1,391 · 2024: $63.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,394 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,394.36 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $937.74 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $794.24 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $678.44 | 2019-2023 | Otezla, Repatha, Prolia |
| Astrazeneca Pharmaceuticals Lp | $673.50 | 2019-2023 | Farxiga, Breztri |
| Abbvie INC. | $653.45 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $638.51 | 2019-2023 | Jardiance |
| Glaxosmithkline, LLC. | $610.84 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $393.75 | 2019-2023 | Trintellix |
| Allergan, INC. | $368.56 | 2019-2020 | |
| Pfizer INC. | $238.03 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $236.06 | 2021-2023 | |
| Astellas Pharma US INC | $206.12 | 2019-2024 | Veozah |
| Amarin Pharma, INC. | $203.58 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $182.82 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $167.24 | 2019-2023 | Xifaxan, Trulance |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.